Skip to main content
Equibles
VNDA logo

VNDA · Vanda Pharmaceuticals Inc. · Documents

Track VNDA — free

Use VNDA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VNDA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.89 +0.07 (+1.83%) Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$230.99M
Shares
60.47M
Volume · Nov 9 152K Avg daily vol (3M) 1.06M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $216.11M up 8.7% 10-K filed Feb 12, 2026 Quarterly report FY2026 Q3 Revenue $69.82M up 24.1% 10-Q filed Oct 29, 2026 Latest results Financial results 8-K filed Oct 28, 2026 Earnings call Q3 2026 earnings call Held Oct 28, 2026
2026
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

Vanda Pharmaceuticals Inc. reported revenue of $69.8 million, up 24%, for the three months ended September 30, 2026; Fanapt® net product sales were $38.8 million, up 24%, and NEREUSTM recorded $1.6 million in net product sales.

Revenue $69.82M ▲ 24.1% Net loss $22.56M Diluted EPS -$0.37
Read from the MD&A section
Oct 28
Earnings call
Q3 2026 earnings call

Vanda Pharmaceuticals reported third-quarter 2026 revenue of $69.8 million, up 24%, and updated revenue guidance to greater than $240 million. Quimilza’s FDA action date was December 12, 2026, and Bisanti was expected to launch in the fourth quarter of 2026.

Oct 28
Current report 8-K
Financial results

Vanda Pharmaceuticals reported Q3 2026 revenues of $69.8 million, up 24%, and operating expenses of $93.3 million, down 18% from Q2. NEREUS reported positive Phase III results, Quimilza’s target action date is December 12, 2026, and guidance exceeds $240 million.

Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $50.53M ▼ 3.9% Net loss $62.51M Diluted EPS -$1.04
May 7
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $51.72M ▲ 3.4% Net loss $48.57M Diluted EPS -$0.82
Apr 23
Proxy statement DEF 14A Meeting Jun 4, 2026
Proxy statement AI summary on its way
Feb 23
Current report 8-K Events of Feb 20
Other events AI summary on its way
Feb 12
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $216.11M ▲ 8.7% Net loss $220.47M Diluted EPS -$3.74
Jan 8
Current report 8-K Events of Jan 7
Other events AI summary on its way
2025
Feb 14
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $198.77M ▲ 3.2% Net loss $18.9M Diluted EPS -$0.33
2024
Showing 1–50 of 174 documents
Key facts CIK 1347178 CUSIP 921659108 13F (30d) 68 filings 52 filers Visit website Investor relations